| abstract |
The present invention is ## STR1 ## [Where: X is a group R 1 —A—NR 4 — or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO 2 , C═O, NR g (C═O) or O (C═O), where R g is hydrogen or optionally substituted by hydroxy or C 1-4 alkoxy. May also be C 1-4 hydrocarbyl); Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in total length; R 1 is hydrogen; a carbocyclic or heterocyclic group having 3 to 12 ring members; or optionally halogen (eg fluorine), hydroxy, C 1-4 hydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino and a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from carbocyclic or heterocyclic groups having 3 to 12 ring members (Wherein the carbon atoms of one or two hydrocarbyl groups may be optionally substituted by an atom or group selected from O, S, NH, SO, SO 2 ); R 2 is hydrogen; halogen; C 1-4 alkoxy (eg methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (eg fluorine), hydroxyl or C 1-4 alkoxy (eg methoxy). Is; R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having 3 to 12 ring members; and R 4 is hydrogen or optionally halogen (eg fluorine), hydroxyl or C 1-4 alkoxy (eg A C 1-4 hydrocarbyl group optionally substituted by methoxy). ] Or a salt thereof, a tautomer thereof, an N oxide thereof, or a solvate thereof, and a combination of two or more additional anticancer agents. |